DOJ Stepping Up Prosecutions Of Medical Providers Who Abuse Prescribing Authority

NPR interview, 11 December 2017
Host: Robert Siegel
“It’s believed that 80 percent of people addicted to heroin today started with prescription painkillers. The over-prescription of opioids in the U.S. has been well documented. NPR’s Robert Siegel speaks with U.S. Deputy Attorney General Rod Rosenstein about how the Department of Justice is ramping up prosecutions of medical providers who abuse their prescribing authority when it comes to opioids.”
Find transcript here.

Drug giants threaten NHS with legal action over cheaper drug that could save £84m a year

The Guardian, 1 November 2017
Author: Sarah Boseley
“Two multinational drug companies are threatening legal action to prevent patients being offered a cheap version of an effective drug against blindness which could save the NHS millions of pounds.”
Find article here.

Health Care Complaints Commission v Qadri [2017] NSWCATOD 155

Decision date: 30 October 2017
“Medical practitioner – inappropriate prescription of drugs of addiction without authority – held guilty of professional misconduct – finding that cancellation of registration is appropriate protective order – costs order made.”
Find decision here.

The Boston-Area Pharmacist Involved in a Deadly Meningitis Outbreak Has Been Cleared of Murder

Time, 26 October 2017
Author: Alanna Durkin Richer
“A pharmacist at a facility whose tainted drugs sparked a nationwide meningitis outbreak that killed 76 people was cleared Wednesday of murder but was convicted of mail fraud and racketeering.”
Find article here.

Health Care Complaints Commission v Robinson [2017] NSWCATOD 147

Decision date: 19 October 2017
“Medical practitioner – disagreement between surgeon and anaesthetist with respect to further conduct of operation – failure to attend to patient in a timely fashion – self prescription of medication – prescription of medication to close family member – finding of professional misconduct – doubt concerning finding of impairment despite concession by medical practitioner that impaired.”
Find decision here.

Health Care Complaints Commission v Noore [2017] NSWCATOD 145

Decision date: 19 October 2017
“Professional misconduct-unsatisfactory professional conduct-medical practitioner consuming illicit drugs-practitioner prescribing drugs to person with whom practitioner had close personal relationship contrary to cl 3.14 of Code of Conduct for Doctors in Australia- prescribing drugs to person when practitioner had no specialist experience for treatment in the subject matter-Practitioner suffering from substance and depressive disorder. Substance use disorder.”
Find decision here.

Newly controversial opioid enforcement law under fire

The Hill, 17 October 2017
Author: Rachel Roubein
“Several lawmakers are pushing to repeal or revisit a law critics say enables the flow of deadly and addictive opioids, hours after President Trump’s drug czar nominee withdrew his name amid the controversy.”
Find article here.

California governor signs drug pricing transparency law

Reuters, 10 October 2017
Author: Bill Berkrot
“California Governor Jerry Brown on Monday signed state legislation requiring drug companies to report certain price hikes for prescription medicines in a move that could set a model for other states to follow. The law, which aims to provide more transparency around pharmaceutical and biotech company pricing methods for their medicines, requires drug manufacturers to give a 60-day notice if prices are raised more than 16 percent over a two-year period. The law also requires health plans and insurers to file annual reports outlining how drug costs affect healthcare premiums in California.”
Find article here.

Knowles v Pharmacy Council of NSW

Decision date: 25 September 2017
“CIVIL AND ADMINISTRATIVE TRIBUNAL – Occupational Division – Stay – additional principle in NSW – protection of health and safety of the public the paramount consideration. In the January 2017 Decision, the Council found that, given a lack of adherence to accepted guidelines and the lack of substantive evidence about the safety and efficacy of certain drugs in humans, the applicant’s practice in relation to the dispensing of peptides was not within accepted standards nor compliant with the Pharmacy Board of Australia (PBA)’s Guidelines on Compounding Medicines (the PBA Guidelines) or otherwise met the public interest.”
Find decision here.